HBOT for Parkinson's Disease in Concord, CA

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, affecting approximately 1 million Americans and 10 million people worldwide. It is caused by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta — a brain region critical for motor control — leading to the characteristic motor triad of tremor, rigidity, and bradykinesia that defines the clinical diagnosis. The pathological hallmark of PD is the accumulation of Lewy bodies: intracellular aggregates of misfolded alpha-synuclein protein that spread through the nervous system in a predictable staging pattern.

The Bay Area and Northern California have a world-class environment for Parkinson's research and care, with UCSF's Weill Institute for Neurosciences and other regional centers providing access to movement disorder specialists and clinical trials. Despite this, the majority of PD patients continue to experience progressive motor and non-motor disability that current dopaminergic therapies — levodopa, dopamine agonists, MAO-B inhibitors — manage but do not arrest. The search for neuroprotective adjunctive therapies that slow the underlying neurodegeneration rather than simply replenishing dopamine is an active area of clinical interest, and HBOT is among the approaches generating the most serious scientific attention.

Parkinson's disease is preceded by years of non-motor symptoms including constipation, REM sleep behavior disorder, hyposmia (loss of smell), and depression. These prodromal features represent a potentially important window for neuroprotective intervention before significant dopamine neuron loss has occurred.

Parkinson's disease is characterized by three converging pathological processes that HBOT has mechanisms to address: neuroinflammation (microglial overactivation and pro-inflammatory cytokine elevation that accelerates dopamine neuron death), mitochondrial dysfunction (the dopaminergic neurons of the substantia nigra are the most metabolically demanding and mitochondria-dependent cells in the brain), and oxidative stress (dopamine metabolism itself generates hydrogen peroxide, making dopaminergic neurons uniquely vulnerable to oxidative damage).

At 1.5 to 2.5 atmospheres of 100% oxygen, HBOT raises cerebral oxygen delivery to levels that directly support mitochondrial oxidative phosphorylation in surviving dopaminergic neurons, reduces the inflammatory microglial activation that drives ongoing neuronal loss, and activates hypoxia-inducible factor 1-alpha (HIF-1α) — a transcription factor that upregulates endogenous antioxidant and neuroprotective proteins. Additionally, HBOT stimulates BDNF (brain-derived neurotrophic factor) and GDNF (glial cell-derived neurotrophic factor), both of which have established neuroprotective effects on dopaminergic neurons in Parkinson's disease models.

Clinical experience and emerging research document improvements in motor function, gait, tremor control, and cognitive performance in PD patients treated with HBOT. A study from researchers at the Shandong University Medical College documented significant improvements in motor function scores and quality of life in Parkinson's patients receiving HBOT. HBOT is used as an adjunct to standard dopaminergic therapy — not a replacement — and is best initiated in earlier stages of disease when the largest population of surviving dopaminergic neurons can benefit from neuroprotective support. Dr. Toth coordinates care with patients' movement disorder specialists throughout the Bay Area, with protocols typically involving 20 to 40 sessions.